Edwards Lifesciences Corp
What to Expect from St. Jude Medical’s Earnings in 2Q16
In 1Q16, St. Jude Medical exceeded analysts’ EPS (earnings per share) estimate of $0.89 as well as the revenue estimate of ~$1.4 billion.
Becton, Dickinson and Company’s 4Q16 Earnings Estimates
Wall Street projected a rise in Becton, Dickinson and Company’s (BDX) adjusted net profit margins. The margins are expected to come in at ~$453 million.
A Look at Boston Scientific’s Valuation Multiples in September
On September 14, Boston Scientific (BSX) was trading at a forward price-to-earnings ratio of 24.4x, compared to the industry’s average PE ratio of 22.4x.
What Really Disrupted Medtronic’s Diabetes Segment Sales in Fiscal 2Q17?
Of Medtronic’s ~$7.3 billion in worldwide revenues in fiscal 1Q17, ~$0.46 billion came from its Diabetes segment, representing ~6% of the company total.
What Led to Edwards Lifesciences’ Stellar Performance in 1Q16?
Edwards Lifesciences (EW) reported ~$697 million in total revenue in 1Q16. Of that, ~$366 million was contributed by the company’s THV (Transcatheter Heart Valve) Therapy segment.
Analysts Raise Their Targets on EW ahead of Its Q3 2018 Results
Edwards Lifesciences is set to release its third-quarter earnings results after the market closes on October 23. Let’s see what to expect.
Analysts’ Recent Recommendations and Target Price for ABT Stock
On May 2, a Reuters survey noted that of 20 brokerage firms tracking Abbott Laboratories, 16 analysts recommended a “buy” or a “strong buy.”
Abbott Laboratories’ Stock Price Performance in July
Year-to-date, ABT stock has risen 12.8%. Over the last month, the stock has returned ~4.0%.
Analysts’ Views on Abbott Laboratories before Q2 2018 Earnings
On July 18, Abbott Laboratories (ABT) is expected to release its earnings results for its fiscal second quarter of 2018.
BSX Stock Regains Momentum after Its Recent Bearish Trend
On February 14, 2018, Boston Scientific stock closed the day at $26.81. The stock was trading near its 50-day moving average of $26.82.
Boston Scientific Stock in the Week Ended September 14
Today, Boston Scientific (BSX) opened at $37.43, down ~0.51% compared to yesterday’s closing price of $37.62.
Can Edwards Lifesciences See Robust Net Profit Margin in 2017?
In its 2Q17 earnings conference call, Edwards Lifesciences (EW) projected 2017 adjusted EPS to fall to $3.65–$3.85, which is higher than the previous $3.43–$3.55.
Illumina Stock Continues Its Bull Run
Illumina (ILMN) reached a 52-week high of $357.93 per share on August 31.
Examining Abiomed’s Gross Margin Trend
In the second quarter of 2018, Abiomed’s (ABMD) cost of revenue rose YoY (year-over-year) to $29.85 million.
Boston Scientific and Edward Lifesciences Settle Patent Dispute
Today, Boston Scientific (BSX) is trading at $36.76, which is a ~4.11% increase from yesterday’s closing price.
Do Analysts See Any Upside for Abiomed Stock?
In this year’s second quarter, Abiomed’s (ABMD) net investment income rose YoY (year-over-year) to $1.67 million from $781,000.
Exploring Abiomed’s Latest Performance Trends
In this series, we’ll explore Abiomed’s financials and valuation along with analysts’ views on its stock.
Why Analysts Are Mostly Positive on Boston Scientific Stock
Boston Scientific stock rose from $24.79 at the close of market on December 29, 2017, to $34.80 at the close of market on November 23.
Taking Stock of Edwards Lifesciences’ Performance
A strong operational performance and steady uptick in Edwards Lifesciences’ stock price has kept investors interested in the stock in 2018.
Gauging Analysts’ Views for NovoCure Stock
Of the five analysts covering NovoCure (NVCR) stock in October, two have given it a “strong buy,” and three have given it a “buy.”
Edwards Lifesciences’ Q3 2018 Earnings Estimates
Edwards Lifesciences is expected to register third-quarter adjusted EPS of ~$1.02, a ~21% YoY (year-over-year) rise.
What to Expect of Edwards Lifesciences’ Q3 2018 Sales
Wall Street expects Edwards Lifesciences to register sales of $0.93 billion in the third quarter, representing a YoY (year-over-year) rise of 10.8%.
EW Stock Returned More than the S&P 500’s Gain in 2018
As of September 28, Edwards Lifesciences (EW) has registered a rise of ~52.5% YTD (year-to-date). In the same period, the S&P 500 has risen ~9.2%.
High Valuation Multiples: Is EW Stock an Expensive Bet?
On September 27, Edwards Lifesciences was trading at a forward PE multiple of 33.2x, while its trailing 12-month PE multiple was 39.3x.
ABT Returns Almost Double the S&P 500’s Year-to-Date Gain
As of September 19, Abbott Laboratories (ABT) has registered a rise of ~17% YTD (year-to-date).
MitraClip Drives Growth, Gets Reimbursement Approval in Japan
On March 19, 2018, Abbott Laboratories (ABT) announced that it had received reimbursement approval for its MitraClip device in Japan.
ABT Gets FDA Approval for World’s Smallest Mechanical Heart Valve
Abbott announced that it received FDA approval for its Masters HP 15-mm rotatable mechanical heart valve, which is the first and only heart valve developed for newborns and infants.
BSX Stock Rises More Than 2% Following EMcision Acquisition
Boston Scientific’s recent stock performance On March 6, 2018, Boston Scientific (BSX) stock closed at $27.41, higher than its 50-day moving average of $27.15 and lower than its 200-day moving average of $27.52. As of March 7, 2018, Boston Scientific’s 52-week high was $29.93 on October 23, 2017, and its 52-week low was $24.02 on March 22, 2017. Factors […]
Wall Street’s Recommendations and Target Prices for BSX
Analysts’ recommendations on Boston Scientific Boston Scientific (BSX) is a leading medical technology company in the United States. The company has been a leading player in minimally invasive therapies for a range of cardiovascular and rhythm management diseases, a space that has become increasingly competitive over the years. Boston Scientific has been expanding in other areas, including endoscopy under its MedSurg […]
Analyzing Edwards Lifesciences’ Recent Acquisitions
In December 2017, Edwards Lifesciences (EW) acquired Harpoon Medical for a total consideration of $119.5 million.
Edwards Lifesciences’ Strong Product Portfolio Bodes Well
Edwards Lifesciences’ (EW) products can be categorized into three therapeutic areas: transcatheter heart valve, surgical heart valve, and critical care.
What Analysts Recommend for Edwards Lifesciences
Of the 22 analysts covering Edwards Lifesciences in February 2018, 17 analysts have given the stock a “buy” or a higher rating.
Exploring Merit Medical Systems’ Business Segments
In 3Q17, Merit Medical Systems’ cardiovascular segment generated revenues of $172.7 million—compared to $150.5 million in 3Q16.
Merit Medical Systems: Analysts’ Ratings in February 2018
Of the eight analysts covering Merit Medical Systems in February, four gave it a “strong buy,” three gave it a “buy,” and one gave it a “sell” rating.
Medtronic’s Minimally Invasive Therapies Group in 3Q18
Overview In fiscal 3Q18, Medtronic’s (MDT) MITG (Minimally Invasive Therapies Group) continued to perform poorly, reporting a YoY (year-over-year) decline of ~16% due to the divestiture of the company’s PMR (Patient Monitoring and Recovery) business in fiscal 2Q18. For details, please read Divestiture of a Part of Medtronic’s PMR Business to Cardinal Health. However, on a constant-currency […]
What Drove Medtronic’s Cardiac and Vascular Group in 3Q18
Cardiac and Vascular Group in fiscal 4Q17 Medtronic (MDT) reported total sales of ~$7.4 billion in fiscal 3Q18. Of that total, ~38% (~$2.8 billion) was contributed by Medtronic’s CVG (Cardiac and Vascular Group). CVG sales grew ~10% YoY (year-over-year) and ~7% on a constant-currency basis. US CVG sales grew ~6% YoY, while developed nation CVG sales […]
Analysts’ Latest Recommendations on Boston Scientific Stock
BSX operates in three business segments: MedSurg, Rhythm Management, and Cardiovascular.
Edwards Lifesciences Expands Portfolio with Harpoon Medical Acquisition
On December 6, 2017, Edwards Lifesciences (EW) announced the completion of its acquisition of Harpoon Medical for $100 million in cash on December 1, 2017.
Stryker’s Inorganic Growth Strategy Continues to Boost Growth
Stryker’s acquisition-driven growth strategy Stryker (SYK) has been growing at a fast pace through inorganic growth. It has undertaken a number of strategic acquisitions recently. In 3Q17, acquisitions contributed approximately 0.6% of the company’s YoY (year-over-year) sales growth, and in the first three quarters of 2017, Stryker acquisitions contributed ~3.2% of the company’s sales growth […]
How Might BSX’s Delayed LOTUS Edge Impact Its Performance?
According to Boston Scientific, the delay will have no material impact on the company’s fiscal 4Q17 and 2017 results.
Why Boston Scientific Stock Fell 9% in Two Days
Boston Scientific (BSX) stock fell ~7.5% on November 28, 2017, triggered by the speculation of bad news.
Medtronic’s Disappointing MITG Business Performance in Fiscal 2Q18
Due to the disappointing fiscal 2Q18 results, Medtronic made a downward revision to its estimates for MITG sales growth in fiscal 2018 to 3.0%–3.5%.
Edwards Lifesciences: Analyst Recommendations in November
In 3Q17, Edwards Lifesciences (EW) reported adjusted sales of ~$838 million, which is an underlying growth of ~13% on a YoY basis. This performance was driven by double-digit organic growth.
What’s BD’s Latest News in the Diabetes Management Market?
On September 19, 2017, Becton, Dickinson, and Company (BDX), or BD, introduced a new pen needle for its pen injection devices.
HVAD Expected to Expand Medtronic’s Presence in LVAD Segment
On September 27, 2017, the FDA approved Medtronic’s HVAD (HeartWare ventricular assist device) system as a destination therapy for advanced heart failure patients.
Medtronic Focused on Efficacy and Safety of LVAD Offerings
Medtronic (MDT) aims to leverage its expertise in implantable pump and electronics segments to further improve Heartware’s LVAD (left ventricular assist device) product portfolio.
New Data Confirms the Efficiency of BSX’s HeartLogic Diagnostic
On September 19, 2017, Boston Scientific announced new data from its MultiSENSE (Multisensor Chronic Evaluation in Ambulatory Heart Failure Patients) study.
Diversified Growth Has Boosted MDT’s Cardiac and Vascular Segment
In the first quarter of fiscal 2018, Medtronic (MDT) reported revenues close to $2.6 billion for its cardiac and vascular (or CVG) group, which is 5% year-over-year (or YoY) growth on a reported basis and 6% YoY growth on an operational basis.
FDA Approvals Could Drive Edwards Lifesciences’ Growth
On June 5, 2017, Edwards Lifesciences’ Sapien 3 valve was approved by the FDA for use in the aortic and mitral valve-in-valve procedure.
Edwards Lifesciences Near 52-Week High: Can It Sustain Momentum?
Edwards Lifesciences (EW), a leader in the artificial heart valve market, has been expanding rapidly amid its new product launches and innovative product pipeline.
Analysts Positive on Edwards Lifesciences: Most Recommend ‘Buy’
Edwards Lifesciences (EW) had tremendous growth in the first half of 2017. The stock has been recovering from the lows in late 2016 and has recently been on a bullish trend.
Boston Scientific’s Expansion Plans in a Fast-Growing Market
Boston Scientific (BSX) has been shifting its focus away from low-growth markets and is trying to enter the high-growth adjacent markets.
Boston Scientific Is Accelerating Category Leadership Strategy
Boston Scientific (BSX) currently has a global market opportunity of $40.0 billion, which is expected to grow to $50.0 billion by fiscal 2020.
MDT’s Diabetes Segment’s Supply Headwinds Expected to Impact Fiscal 2018
In fiscal 1Q18, Medtronic’s (MDT) Diabetes Group reported revenues of $449 million, which represents a year-over-year sales decline of ~1%.
Edwards Lifesciences Focuses on Indication Expansion of SAPIEN 3 in 2017
To further expand the label of its transcatheter heart valve (or THV), SAPIEN 3, Edwards Lifesciences (EW) is currently involved in enrolling patients in its EARLY-TAVR trial.
Edwards Lifesciences’ Mitral Regurgitation Segment
To diversify its focus beyond aortic structural heart conditions, Edwards Lifesciences (EW) acquired CardiAQ Valve Technologies in August 2015.
Edwards Lifesciences Focuses on Launch of SAPIEN 3 Ultra and CENTERA Valves
Edwards Lifesciences’ (EW) SAPIEN 3 Ultra system is a next-generation platform, with expandable Axela sheath technology and on-balloon delivery design.
Edwards Lifesciences: Focused on Inspiris Resilia and Konect
To extend the durability of the Inspiris Resilia surgical aortic valve, Edwards Lifesciences (EW) has incorporated a new tissue platform, Resilia tissue.
Can Edwards Intuity Elite Boost Edwards Lifesciences’ Revenues?
With the Edwards Intuity Elite valve system, Edwards Lifesciences aims to offer a minimally invasive therapy to complex aortic stenosis patients.
TAVR Therapy Expected to Witness Solid Growth in Demand in 2017
Demand for transcatheter aortic valve replacement (or TAVR) therapy has been robust in the US, mainly due to the opening of new heart valve centers and relatively lower competition.
Transcatheter Heart Valve Therapy: Growth Driver for Edwards Lifesciences
In 2Q17, Edwards Lifesciences’ (EW) Transcatheter Heart Valve Therapy segment reported revenues close to $316 million, which represents year-over-year growth of ~28%.
Medtronic’s Strong 4Q17 Profits Beat Analyst Expectations
Medtronic (MDT) reported an operating margin of 30.7% of total sales in fiscal 4Q17 on a constant currency basis.
What Do Analysts Recommend for Boston Scientific?
Let’s look at Wall Street analysts’ recommendations and target prices for Boston Scientific (BSX) over the next 12 months.
BSX’s Resonate ICD and CRT-D Defibrillators Get US Approval
On May 9, 2017, Boston Scientific (BSX) announced the FDA approval of its Resonate family of products, including its ICD and CRT-D systems.
Discussing Boston Scientific Stock’s Recent Movements
Boston Scientific (BSX) was trading at $27.2 on May 25, 2017. It had a 50-day moving average of $25.8 and a 200-day moving average of $23.9.
Behind BD’s Recent Strategic Initiatives and Product Launches
In its diabetes business, BD (BDX) is working with Medtronic (MDT) to relaunch a new infusion set, after the temporary suspension of its shipments.
Novartis’s Recent Developments
Novartis (NVS) reported flat revenues at constant exchange rates during 4Q16 as well as in fiscal 2016. This was driven by growth in Sandoz revenues.
Analyzing the BD Medical Segment’s Product Pipeline
Becton, Dickinson and Company (BDX) generates ~$1 billion from its Infection Prevention business.
New Structural Heart Initiatives: Edwards’ Key Growth Drivers in 2017 and Beyond
Edwards Lifesciences estimates that mitral regurgitation patients total 2.5 million–3.5 million. But only ~25,000 patients per year are treated in the US.
Edwards Lifesciences’ Acquisition of Valtech Cardio: Must-Know Details
On November 28, 2016, Edwards Lifesciences (EW) announced the acquisition of Valtech Cardio for $340 million in stock and cash.
Inside Edwards Lifesciences’ THV Product Pipeline and Future Growth Estimates
Edwards Lifesciences (EW) has a robust product pipeline in its THV (transcatheter heart valve) segment, with Sapien 3 as the segment’s leading product.
Trial Data Affirms Positive Results of HeartLogic Diagnostic Service
Developed by Boston Scientific (BSX), HeartLogic is a system of sensors that can be attached to defibrillator devices. These sensors can monitor the patient and predict heart failure events.
What You Need to Know About the Micron-Inotera Deal
A major part of Micron Technology’s (MU) transition to the 20 nm node involves Taiwan’s (EWT) Inotera and its joint venture with Nanya Technology.
Understanding Medtronic’s Weak CVG Segment Performance in Fiscal 2Q17
Of Medtronic’s ~$7.3 billion in worldwide revenues in fiscal 2Q17, ~$2.6 billion came from Medtronic’s CVG segment, representing ~35% of the company total.
Edwards Lifesciences Updates 2016 Guidance after 3Q16 Earnings
Edwards Lifesciences revised its 2016 guidance after reporting a strong 3Q16. The company maintained its sales guidance for the year at the high end of the $2.7 billion–$3 billion range.
How EW’s Gross Profit Margins Were Affected in 3Q16
Edwards Lifesciences (EW) reported falling revenue in 3Q16. Its gross profit margin fell and was reported to be ~72.8% of its total revenue, compared to ~76.2% in 2Q16.
Boston Scientific’s 3Q16 Earnings Beat Analysts’ Estimates
Boston Scientific (BSX) reported its 3Q16 earnings on October 26, 2016. It registered adjusted EPS of $0.27 in 3Q16. It had ~12.5% YoY growth.
New Data Affirm Benefits of Medtronic’s Valiant Captivia
On September 20, 2016, Medtronic posted its new safety and efficacy data for its Valiant Captivia Thoracic Stent Graft System.
Incyte’s Profitability Improves, Allowing for Revised Guidance
Incyte (INCY) reported revenues of $246.3 million in 2Q16, an increase of 51% compared to $163 million in 2Q15.
What Explains the Columbia Select Large Cap Growth Fund’s Poor Showing?
The short-term performance of the Columbia Select Large Cap Growth Fund – Class A (ELGAX) is excellent, and the past six months have been great for the fund.
Analyzing Medtronic’s Sales Growth by Segment in 1Q17
Medtronic (MDT) operates under four segments: Cardiac and Vascular Group (or CVG), Minimally Invasive Therapies Group (or MITG), Restorative Therapies Group (or RTG), and Diabetes Group.
How Are Danaher’s Returns Compared to Its Industry Peers’?
Danaher’s ROIC fell steadily from 15.5% in 2006 to 8.5% in 2015, indicating that it has probably had fewer high return reinvestment opportunities since then.
Medtronic’s Minimally Invasive Therapies Group: Major Drivers
Medtronic plans to launch more than 80 products over the next three years.
What Drives Medtronic’s Cardiac Vascular Group’s Revenues?
Medtronic’s (MDT) Cardiac and Vascular Group (or CVG) is its largest segment.
How the Healthcare Sector Has Hurt ELGAX Year-to-Date in 2016
On May 27, 2016, the Columbia Select Large Cap Growth Fund Class A (ELGAX) had fallen by 6.5% YTD (year-to-date) in 2016.
How Did Edwards Lifesciences’ Critical Care Segment Fare in 1Q16?
Edwards Lifesciences (EW) reported ~$697 million in total revenue in 1Q16. Of that, ~$134 million was contributed by the company’s Critical Care segment.
St. Jude Medical’s Market Position and Opportunities
St. Jude Medical has a comprehensive product portfolio in the atrial fibrillation and heart failure therapy areas. The acquisition of Thoratec added to its heart failure therapy product segment.
A Look at Edwards Lifesciences’ Future Opportunities
Currently, Edwards Lifesciences’ Sapien 3 and Sapien XT are approved by the FDA to be used in high-risk patients only.
Stryker’s 4Q15 Revenues Expected to Witness Growth
Wall Street has estimated Stryker’s 4Q15 revenues to be about $2.7 billion, representing a growth of around 3.6% on a YoY (year-over-year) basis compared.
Medtronic Faces Risks from Integrating with Covidien
Medtronic is a highly diversified company in terms of geographic exposure. Some of the risks faced by Medtronic include integration and litigation risks.
Why Technology Is a Key Driver in the US Medical Device Industry
Traditionally, the United States has been home to the most advanced technological inventions in the medical device industry.
How Reimbursement Models Impact the Medical Device Industry
Coverage, coding, and payment are essential elements to obtaining adequate reimbursement for a new medical device.
Evaluating Medtronic’s Cardiac and Vascular Devices Segment
Medtronic’s Cardiac and Vascular segment consists of Cardiac Rhythm and Heart Failure, Coronary and Structural Heart, and Aortic and Peripheral Vascular.
How Are Cardiovascular Devices Classified?
The US cardiovascular device market is dominated by cardiac rhythm management (or CRM) devices.
Nuvasive Traded above Its 100-Day Moving Average
Nuvasive (NUVA) gained 1.3% on October 12, 2015. The stock went up on the news that the FDA gave clearance for NUVA’s cervical corpectomy cage.
How are XLV’s Moving Averages Trending?
Out of 56 stocks in XLV’s portfolio, a total of 32 stocks were trading above their 20-day moving average.
XLV Gained 1% as 60% of Portfolio Ended Positively for the Day
XLV outperformed the broader market representative SPDR S&P 50 ETF on October 1, 2015. SPY rose by 0.26% , compared with XLV’s 1.01%.
Healthcare Sector Recovery, Led ETF by 0.92%
The healthcare sector rebounded on Tuesday, September 29, after being rattled the week prior.